RxDoctor Payments Data

Christine Robert, MD

Internal Medicine · Metairie, LANPI 1124587381

Payments from drug & device makers

$3,458in general payments, 2019–2025

Across 193 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$699
  • AstraZeneca$577
  • Lilly USA, LLC$300
  • Boehringer Ingelheim$238
  • Exact Sciences$232
  • Bayer$215
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,458 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$32,205
Medicare patients
105
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$47,940
EliquisApixaban22$22,671
MyrbetriqMirabegron12$6,582
Rosuvastatin Calcium84$1,158
Pantoprazole Sodium115$1,080
Gabapentin94$983
Levothyroxine Sodium97$930
Albuterol Sulfate HfaAlbuterol Sulfate29$904
Atorvastatin Calcium170$879
Pravastatin Sodium34$804
Metoprolol Succinate58$731
Irbesartan20$666
Amlodipine Besylate138$604
Trazodone Hcl64$589
Losartan Potassium80$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$179$47,94041 claims
PfizerEliquis$699$22,67122 claims
Astellas Pharma US IncMyrbetriq$34$6,58212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →